Considerations from the IQ induction working group in response to drug–drug interaction guidances from regulatory agencies
Niresh Hariparsad(Amgen (United States)), Donald Tweedie(Amgen (United States)), Heidi J. Einolf, Robert L. Walsky(Merck & Co., Inc., Rahway, NJ, USA (United States)), David B. Buckley(Amgen (United States)), Barry Jones(AstraZeneca (South Korea)), Jairam Palamanda, Michael A. Mohutsky(Amgen (United States)), Michael Sinz(Rutgers, The State University of New Jersey), Y. Amy Siu(Amgen (United States)), Shannon Dallas(Amgen (United States)), George Zhang(Air Force Medical University), Liangfu Chen(Sun Yat-sen University), Diane Ramsden(Alnylam Pharmaceuticals (United States)), Joshua G. DeKeyser(Amgen (United States)), Conrad A. Fung(Vertex Pharmaceuticals (United States)), Jane R. Kenny(Amgen (United States)), Suresh K. Balani(Amgen (United States))
Cited by 0
Related Papers
Reproducing human and cross-species drug toxicities using a Liver-Chip
|Science Translational Medicine|2019|478
CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes
|Drug Metabolism and Disposition|2002|447
Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice
|Chemical Research in Toxicology|1998|312
Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole
|Oncogene|2006|211
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
|Antimicrobial Agents and Chemotherapy|2012|186